Arcturus Therapeutics (ARCT) Competitors $15.82 +0.09 (+0.57%) (As of 10:00 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends ARCT vs. GLPG, XNCR, EVO, ARQT, NRIX, RCUS, KNSA, IMCR, OCUL, and MESOShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Galapagos (GLPG), Xencor (XNCR), Evotec (EVO), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Galapagos Xencor Evotec Arcutis Biotherapeutics Nurix Therapeutics Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Galapagos (NASDAQ:GLPG) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts recommend GLPG or ARCT? Galapagos currently has a consensus price target of $30.75, suggesting a potential upside of 14.35%. Arcturus Therapeutics has a consensus price target of $66.75, suggesting a potential upside of 321.93%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the media favor GLPG or ARCT? In the previous week, Arcturus Therapeutics had 3 more articles in the media than Galapagos. MarketBeat recorded 9 mentions for Arcturus Therapeutics and 6 mentions for Galapagos. Galapagos' average media sentiment score of 0.42 beat Arcturus Therapeutics' score of 0.30 indicating that Galapagos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galapagos 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has higher valuation and earnings, GLPG or ARCT? Galapagos has higher revenue and earnings than Arcturus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$260.09M6.81$229.12MN/AN/AArcturus Therapeutics$142.47M3.01-$29.73M-$2.22-7.13 Is GLPG or ARCT more profitable? Galapagos has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. Galapagos' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A Arcturus Therapeutics -36.39%-22.39%-14.81% Do insiders and institutionals hold more shares of GLPG or ARCT? 32.5% of Galapagos shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 2.9% of Galapagos shares are held by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, GLPG or ARCT? Galapagos has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.62, indicating that its share price is 162% more volatile than the S&P 500. Does the MarketBeat Community prefer GLPG or ARCT? Galapagos received 28 more outperform votes than Arcturus Therapeutics when rated by MarketBeat users. However, 65.96% of users gave Arcturus Therapeutics an outperform vote while only 64.10% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformGalapagosOutperform Votes46664.10% Underperform Votes26135.90% Arcturus TherapeuticsOutperform Votes43865.96% Underperform Votes22634.04% SummaryArcturus Therapeutics beats Galapagos on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$428.52M$6.85B$5.15B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-7.1310.79135.4217.51Price / Sales3.01286.571,184.62142.21Price / CashN/A56.6540.4237.95Price / Book1.525.404.894.94Net Income-$29.73M$152.04M$118.71M$225.59M7 Day Performance-11.87%-4.19%15.74%-1.07%1 Month Performance-2.77%2.70%15.70%7.23%1 Year Performance-44.82%17.16%34.85%22.97% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.7024 of 5 stars$15.82+0.6%$66.75+321.9%-45.5%$428.52M$142.47M-7.13180Analyst ForecastNews CoverageGap UpGLPGGalapagos0.7405 of 5 stars$26.99+0.6%$30.75+13.9%-31.6%$1.78B$260.09M0.001,123XNCRXencor4.1787 of 5 stars$24.84+3.4%$36.56+47.2%+19.7%$1.74B$168.34M-7.51280EVOEvotec1.4795 of 5 stars$4.69+4.5%$5.93+26.5%-56.6%$1.66B$777.05M0.005,061Short Interest ↓Gap DownARQTArcutis Biotherapeutics0.8059 of 5 stars$13.34+5.1%$15.50+16.2%+509.0%$1.56B$138.71M-7.58150Options VolumeNews CoverageNRIXNurix Therapeutics2.8431 of 5 stars$21.19+4.5%$30.35+43.2%+133.3%$1.50B$56.42M-6.97300RCUSArcus Biosciences2.7843 of 5 stars$16.25+1.1%$34.00+109.2%-11.3%$1.49B$117M-5.11500KNSAKiniksa Pharmaceuticals2.6661 of 5 stars$20.40+1.0%$36.60+79.4%+13.9%$1.47B$384.10M-147.36220Positive NewsIMCRImmunocore2.6347 of 5 stars$29.05+0.5%$65.64+125.9%-54.2%$1.45B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.797 of 5 stars$8.98+3.3%$16.71+86.1%+129.5%$1.41B$58.44M0.00267Positive NewsMESOMesoblast1.2998 of 5 stars$12.18+3.6%$11.50-5.6%+484.6%$1.39B$5.90M0.0080News CoverageGap Up Related Companies and Tools Related Companies Galapagos Alternatives Xencor Alternatives Evotec Alternatives Arcutis Biotherapeutics Alternatives Nurix Therapeutics Alternatives Arcus Biosciences Alternatives Kiniksa Pharmaceuticals Alternatives Immunocore Alternatives Ocular Therapeutix Alternatives Mesoblast Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARCT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
